New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Passage Bio, Inc.

PASG

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

3.92 0.31 +8.59%
Market cap
$11.6M
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
1.0×
Payout ratio
—

Ratios over time FY19 to FY25

Returns on capital

ROIC was 0.00% in FY25, the highest of these seven years.

ROEROIC
FY19FY20FY21FY22FY23FY24FY25
ROE133.4%−90.3%−59.5%−52.4%−65.3%−75.1%−113.8%
ROIC0.0%0.0%−4025.0%−735.8%0.0%0.0%0.0%

Debt

Net debt is 0.96× a year’s EBITDA. Debt is 0.00× equity.

Debt / equityNet debt / EBITDA
FY18FY19FY20FY21FY22FY23FY24FY25
Debt / equity0.0×0.0×0.0×0.0×0.0×0.0×0.0×0.0×
Net debt / EBITDA2.5×4.3×2.7×1.7×1.4×1.1×1.1×1.0×
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17
Current Ratio
2.07 4.07 7.22 10.74 11.02 14.98 45.04 108.79 —
Net Debt/EBITDA
0.96 1.11 1.07 1.42 1.74 2.73 4.29 2.46 —
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
ROE
(113.78%) (75.07%) (65.29%) (52.35%) (59.48%) (90.34%) 133.38% 37.32% —
ROA
(55.28%) (51.21%) (51.80%) (45.48%) (54.28%) (44.31%) (43.04%) (76.33%) —
ROIC
0.00% 0.00% 0.00% (735.76%) (4,024.99%) 0.00% 0.00% — —
Return on Tangible Assets
(158.14%) (94.16%) (87.30%) (67.65%) (58.05%) (37.56%) (27.97%) (38.56%) —
Free Cash Flow per Share
(9.56) (15.59) (28.65) (45.37) (57.18) (42.56) (196.36) (0.41) —
Book value per Share
5.91 19.90 40.66 73.99 119.47 157.82 (265.59) (0.27) —
Free Cash Flow
(30.34) (47.99) (78.41) (123.48) (152.52) (82.17) (41.59) (18.57) —
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 12, 2026